Genmab — Januar 2018

[E_L]

Is it pure coïncidence that this company (in Utrecht, just next to Genmab) announces first dosing of bispecific antibody targeting HER2 and HER3 receptors today?? Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=262078

[Sukkeralf]

Det er bare et hårdt prøvet target

[E_L]

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens https://clinicaltrials.gov/ct2/show/NCT03412565?term=daratumumab+OR+ofatumumab&lupd_s=01%2F25%2F2018&rank=4

[E_L]

this could become a very important study, backbone Dara, choose what combo you want, D-VRd , D-VMP or D-Rd.

[E_L]

completion date sept 19, very fast?

[Bulder]

Phase 2. Will they file?

[AaBforever]

Det går squ´meget godt nu

[AaBforever]

Som sagt før " Genmab er som en rutschebane i Fårup...det går SÅ hurtigt ned og OP

[E_L]

good point. thinking out-loud; we already have the SubQ vs IV study which is Phase 3; maybe this is the Ph2 we need in the middle to get that one approved?

[E_L]

we had a similar situation before, no?

[E_L]

I mean, the IV combo's should be approved by then?

[E_L]

sorry, not should be , WILL be

[Bulder]

Do you ask Winkel if this means that these 2 studies can be the basis for an overall approval of sc in all lines and settings?

[E_L]

ok - good idea

[Bulder]

If so, it means that sc can be launched in 2020. - Just like Novod predicts.

[Helge_LarsenPI-redaktør]

Vi kan vist stadig være enig om at shorterne i aktien er meget venlige og humane. Vi ser absolut ingen aggressivitet og forsøg på at trykke kursen ned under støttepunkter og udløse stop loses over en bred kam.

[Helge_LarsenPI-redaktør]

Enig med Pensionisten. Der er udmattelse at spore. Det har vi dog prøvet før gennem årene.

[Helge_LarsenPI-redaktør]

Jeg formoder, at vi kursmæssigt danner base for øjeblikket. Nyorienteringen starter så efter næste Q&A d. 22. februar.

[E_L]

Hmmm… i actually think bears have done well again this week; I think there was plenty down pressure Tuesday and yesterday morning and we close the week way below the weekly high…. In this huge bull market where everything seems to be going through the roof and makes new highs Genmab needs another 30% to even get there…

[E_L]

Anyways, TA: The 1194.5 high last week was just shy of the 38.2% retracement from the 1015 low. Yesterday we almost hit the 61.8% retracement of that level (1084). If we manage to hold that, an equal leg move (ab=cd) would get us to 1269. Note that the 1240-1250 area was resistance in november and early december. 1252 is the 50% retracement from the 1015 low.